S
Suzanne Travers
Publications - 11
Citations - 7038
Suzanne Travers is an academic researcher. The author has contributed to research in topics: Infliximab & Ulcerative colitis. The author has an hindex of 8, co-authored 11 publications receiving 6534 citations.
Papers
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
Jeffrey S. Hyams,Wallace Crandall,Subra Kugathasan,Anne Griffiths,Allan Olson,Jewel Johanns,G Liu,Suzanne Travers,R. Heuschkel,James Markowitz,Stanley N. Cohen,Harland S. Winter,Gigi Veereman Wauters,G. D. Ferry,Robert N. Baldassano +14 more
TL;DR: Pediatric patients responding to an induction regimen of infliximab were more likely to be in clinical response and remission at week 54 without dose adjustment when their maintenance therapy was given every 8 weeks rather than every 12 weeks.
Journal ArticleDOI
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
Stephen B. Hanauer,Carrie L Wagner,Mohan Bala,Lloyd Mayer,Suzanne Travers,Robert H. Diamond,Allan Olson,Warren Bao,Paul Rutgeerts +8 more
TL;DR: Reduced antibody formation and greater clinical benefit were observed with an induction regimen followed by maintenance treatment compared with a single dose followed by episodic retreatment in Crohn's disease patients treated with infliximab.
Journal ArticleDOI
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Gary R. Lichtenstein,Allan Olson,Suzanne Travers,Robert H. Diamond,Donny M. Chen,Michelle L. Pritchard,Brian G. Feagan,Russell D. Cohen,Bruce Salzberg,Stephen B. Hanauer,William J. Sandborn +10 more
TL;DR: Although unadjusted analyses suggested that patients who received infliximab were twice as likely to develop SSOs, multivariable analysis adjusting for other factors demonstrated that only disease duration, disease severity, ileal disease, and new corticosteroid use were significantly associated with SSO development.